Market Overview

Dr. Reddy's Launches Sildenafil Tablets

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched
Sildenafil Tablets (20 mg), a bioequivalent generic version of REVATIO®
(Sildenafil) Tablets in the US market on November 16, 2012,
following the approval by the United States Food & Drug Administration
(USFDA) of Dr. Reddy's ANDA for Sildenafil Tablets.

The REVATIO® brand had U.S. sales of approximately $338.67
Million for the most recent twelve months ending September 2012
according to IMS Health*.

Dr. Reddy's Sildenafil Tablets in 20 mg are available in 90 count bottle
sizes.

Disclaimer

This press release includes forward-looking statements,

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (RDY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional